Very happy to share our review on Hippo-YAP/TEAD pathway which I had the opportunity to contribute during my rotation at @UTMDAnderson
I’m grateful for those months of learning & the opportunity to take part in projects like this. Thanks @DrMirallas, Dr Yap & all the co-authors
🚀 Our review on Hippo–YAP/TEAD pathway is now out in Pharmacology & Therapeutics @Sciencedirect @Scopus
We discuss the:
🧬 Biology
💊 Emerging drugs
🎯 Early clinical proof-of-concept
❌ Resistance mechanisms
☣️ Toxicities and where the field may go next
Thanks Dr. Yap for the support and mentorship @UTMDAnderson and to the rest of co-authors for their great work Dr. Tan, Crous, Selvadurai and Lynch👏🏽
#YAP #TEAD #HippoPathway #CancerResearch #DrugDevelopment
@OncoAlert @myESMO @_SEOM @ASCO
👇🏽👇🏽 Full article:
sciencedirect.com/science/ar…
2
62
Carme retweeted
Proud to be at #ESMO2026 in Madrid with the Clínic Barcelona team 💙💚
Over 30 scientific contributions across tumour types, reflecting the work of so many colleagues.
Thank you to everyone involved for your dedication to research and patient care.
@hospitalclinic @idibaps
Carme retweeted
Que emocionant, el meu primer professor de la primera classe a la Facultat!
Quan algú fa les coses molt bé, amb molt esforç i constància, amb vocació d'ensenyar i aprendre, amb humilitat i discreció i, a més, ho fa de manera excel·lent, passa això. El Prof Dr @ToniTrilla s'ha jubilat com a Degà de Medicina de la @UniBarcelona la primera de l'Estat
Carme retweeted
☝🏼Eo! Estás en SEOM? Pues aquí os dejo 2 pósters espectaculares en #SEOM26 de las Dras. Carlota Rubio y @carmecrouss 👏🏼
@hospitalclinic
Dra. Rubio - 🧬 Un atlas unicelular del microambiente tumoral en cáncer de mama, identificando un gradiente inmunológico y un subgrupo HER2+ especialmente “caliente”
Dra. Crous -🛡️ Una revisión sistemática y metaanálisis del perfil de toxicidad inmunomediada órgano-específica y mortalidad en tumores genitourinarios
2 trabajos de muchísimo nivel y 2 paradas obligatorias en el congreso 🚨
Speechless 😶 ¡felicidades a ambas!
@_SEOM @OncoAlert
💥Póster destacado #SEOM26
📍irAEs órgano-específica y mortalidad asociada a ICI en tumores GU
⚠️ irAEs: 45.3% ady vs. 28.6% M1
▶️ Alter endocrinas ++ en ady > M1
▶️ Nefritis ++ en M1 > ady
☠️ 21 muertes por ICI, siendo la 🫁 la causa + frecuente
Carme retweeted
🎉 Cisplatin or Carboplatin? That is the question
✔️ Only high-certainty evidence signal was found for Cis>Carbo in ORR urothelial, and the no PFS difference Cis=Carbo in ovarian.
❌ Most of the guidelines-based recommendations are low or ultra low GRADE based evidence
🫂 An honour to work with great colleagues and keep learning
Prof Harrington @MattGalsky Prof Colombo @EnriquetaFelip Dr Rodon @juditsanz Dr Pereira @PaulJiL
@OncoAlert @brunolarvol @OncBrothers @myESMO @ASCO @_SEOM @UTMDAnderson
Full manuscript 👇🏽👇🏽
jamanetwork.com/journals/jam…
The eternal question in solid tumor oncology, almost Shakespearean in its persistence
When is Cisplatin better than Carbo? When are they equivalent?
Excited to share our new paper in @JAMANetworkOpen where we examined the certainty of evidence of the 11 major meta-analyses (12 683 pts) on which guidelines based their recommendations
✴️Several efficacy variables have low or very low level of certainty
✳️Only high-certainty evidence signal was found for Cis>Carbo in ORR urothelial, and the no PFS difference Cis=Carbo in ovarian.
🟡Despite high heterogeneity impacting GRADE across tumour types, toxicities show known correlations
The story does not end here, highlighting the utility of meta-data appraisals and current evidence gaps. We might not need new trials, just greater access to data from completed studies
#oncology @myESMO @ASCO
👏An honour to have worked with and learned from this faculty
Prof Harrington @MattGalsky Prof Colombo @EnriquetaFelip Dr Rodon @juditsanz Dr Pereira @DrMirallas
@OncoAlert @brunolarvol @OncBrothers
Contenta d’haver pogut participar al 5è congrés de la Societat Catalana d’Oncologia parlant sobre les novetats en la neoadjuvància del TVMI
Ben acompanyada per l’equip d’oncologia de l’@hospitalclinic
@SCBdOncologia
1
77
💥Poster session #ASCO26
📍Clinical impact & molecular profiling of PTENloss & TMPRSS2:ERG in mHSPC
➕correlation between PTENloss & TE+
❌ PTENloss/TE- had the worst clinical outcomes
✅ Among PTENloss, TE+ presented better outcomes>TE-
🧬 PTENloss/TE+ had enrichment of PI3K – at Chicago, IL
Carme retweeted
#ASCO26
🚀 After office @ASCO Day 2
Networking with colleagues from @VHIO @hospitalclinic @UTMDAnderson @carmecrouss
@OncoAlert – at Chicago, IL
Carme retweeted
Day#2 of #AACR26! Carpe Diem! With my well dressed phase 1 fellows! @MDAndersonnews
Si t’interessa l’oncologia mèdica, no dubtis en venir a les portes obertes de l’@hospitalclinic el dia 20 de març!! T’estarem esperant 😊 Pots contactar-nos si tens qualsevol dubte👇🏻
Te interesa la Oncología Médica? Ven el día 20 de marzo a las puertas abiertas del @hospitalclinic a conocer nuestro servicio o contáctanos para cualquier duda! #MIR #MIR2025 #residentsCLÍNIC #CLÍNIC #medicina #residentes #oncología #oncologíamédica
7
444
Carme retweeted
Has fet el #MIR2024# i estàs interessat en Oncologia Mèdica?😄
Vine a la nostra Jornada de Portes Obertes!
T’esperem!
@hospitalclinic @prat_aleix @MuozMateu @badamo20 @LauraMezquitaMD
👇🏻🧠 – at Figueres, Spain
We are glad to present our paper about the Impact of the TERTp C250T Mutation on Glioblastoma Prognosis🧠 Great team effort lead by @EPineda_ONCO and Dr. Balaña🌟
mdpi.com/2072-6694/16/4/735
3
397
🚩Mensajes clave de Javier Marco.
Un PS ≥2, la enfermedad oncológica metastásica o la imposibilidad de realizar tratamiento oncoespecífico tras el ingreso en UCI se asocian con una > mortalidad al año en los supervivientes a la UCI.
👉 El médico internista que realiza asistencia compartida en unidades de oncología juega un papel central y debe aportar la visión holística y ejercer de enlace entre l@s especialistas en oncología y l@s de cuidados intensivos.
👉Pacientes en curso de tratamientos neo/adyuvantes o con enfermedades oncológicas EIV candidatos a tratamientos de beneficio potencialmente excepcional con PS 0-1 y buena calidad de vida se benefician de ingresar en UCI.
@javi_mrco #44SEMI
Carme retweeted
I am glad to share our latest publication where we highlight the use of targeted nanoparticles as a clear new therapeutic strategy for solid tumors. This approach reduces side effects while enhancing the efficacy of tyrosine kinase inhibitors.
mdpi.com/2218-273X/13/11/164…
Great presentation by @Teresa_Gorria at #EANO2023 of our study on TERTp C228T mutation as a prognostic factor in patients with Glioblastoma IDH-wt 🧠🧬
@EPineda_ONCO
@BalanaCarme
Check out our results 👇👀 – at Rotterdam, The Netherlands
Carme retweeted
Heading to Rotterdam #EANO2023📍Grateful to present the results of our study on TERTp C228T mutation as a prognostic factor in patients with Glioblastoma IDH-wild type 🧠🧬
@carmecrouss
@EPineda_ONCO
@BalanaCarme
& co
🕝 Friday, September 22nd, 18h. Poster Pitch Session
Carme retweeted
Un año más juntos en el congreso #SEOM23 🙌🏽📍 #resisOncClinic participando en:
-Caso Clínico Molecular: Sd. Cowden y cáncer de mama🧬-Dr.Javi Muñoz
-Comunicación GU: Horario de infusión IO y Ca.Renal⏱️ @lauragnzaguado @laiafernandezm
-Póster destacado en SNC🧠@carmecrouss &🙋🏽♀️
Carme retweeted
MEDICINA AMB PERSPECTIVA DE GÈNERE #COMBinem
👩⚕️Ponents: Dra. Blanca Collvinent i Dra. Mireia Puig
🗓️ 27 de Juny
⏰ 18:00
📍 Sala Panoràmica COMB i online.
Ens parlaran de la importància d'aplicar la perspectiva de gènere per oferir una mirada més àmplia i una atenció de qualitat















































